Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have proven cardiovascular benefits in patients with type 2 diabetes (T2D). This self-controlled case series study aims to evaluate whether metformin use and SGLT2i-associated erythrocytosis influence its cardiovascular benefits. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Carlos King Ho, Lau, Kristy Tsz Kwan, Tang, Eric Ho Man, Lee, Chi Ho, Lee, Carmen Yu Yan, Woo, Yu Cho, Au, Ivan Chi Ho, Tan, Kathryn Choon Beng, Lui, David Tak Wai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166572/
https://www.ncbi.nlm.nih.gov/pubmed/35658864
http://dx.doi.org/10.1186/s12933-022-01520-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166572/
https://www.ncbi.nlm.nih.gov/pubmed/35658864
http://dx.doi.org/10.1186/s12933-022-01520-w

Ejemplares similares